Enlivex Clears DSMB Safety Review in Phase IIb Knee Osteoarthritis Trial
ENLV sits 18% above its 52-week low of $1 on light trading volume (0.3× avg).
Summary
Enlivex said its independent DSMB completed an interim safety review of 85 patients in the Phase IIb Allocetra knee osteoarthritis trial and cleared continued enrollment as planned. No efficacy data was disclosed.
Key Events · Product Development and Regulatory · ENLV
-
DSMB Clears Trial to Continue
The independent Data and Safety Monitoring Board completed an interim safety review of data from 85 patients randomized and dosed in the Phase IIb Allocetra knee osteoarthritis trial and confirmed the safety profile allows enrollment to continue as planned.
-
Trial Design and Enrollment Target
The randomized, double-blind, placebo-controlled trial is planned to enroll approximately 182 patients at sites in the United States, Denmark and Poland, with pain and physical function endpoints measured at three and six months.
-
Safety Only, Efficacy Still Pending
The review covered safety, not efficacy; the company said it looks forward to reporting topline data, but the filing gives no date for that readout.
-
Funding and Listing Pressure
The news lands against a $7.5M registered direct offering of which only the first $500,000 has closed, with $7.0M due in ten monthly tranches, and a Nasdaq delisting notice received 2026-10-27.
Analysis · ENLV · Crypto Assets
The independent safety board reviewed data from 85 dosed patients and allowed the Allocetra Phase IIb trial to continue unchanged, removing the main near-term risk of a clinical hold or protocol change. That matters because the company is running on a $500,000 first tranche of a $7.5M offering, with the remaining $7.0M arriving in ten monthly installments, and it faces a Nasdaq delisting notice received 2026-10-27 — so keeping the trial on schedule is the core of the equity story. The readout is safety only; efficacy topline data is still ahead, and no date is given in the filing.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $1.18 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.00 to $434.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.